Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

European Research Council grant · Running

OligoBackMod Oligonucleotide Backbone Modifications

Coordinator
Universitat Basel, Switzerland
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335537

What the project is doing

In the project's own words, from its summary on CORDIS.

Therapeutic oligonucleotides are rapidly emerging as novel modalities for the treatment of several previously unaddressable diseases. The development of oligonucleotide therapeutics has thereby been significantly driven by chemical modifications that enhance nuclease resistance, pharmacokinetic properties, and target engagement. Especially the modification of the phosphorus site at the internucleoside linkage, in particular by the replacement of an oxygen with sulfur in the form of phosphorothioates, proved to be decisively beneficial.

However, despite the immense and immediate impact, the current phosphorus backbone chemistry to form modified functionalities, such as phosphonates and phosphoramidates, remained severely limited by the classical reactivity at phosphorus. Expanding the chemical space of oligonucleotide backbone modifications requires transformations that can operate under mild conditions compatible with sensitive nucleic acid substrates.

Here, we propose to explore the innovation potential of an unusually versatile method for oligonucleotide backbone modification developed in the framework of an ERC-CoG funded project. With the intellectual property protected by the filing of four patent applications, this Proof of Concept project aims to explore a stereoselective library creation by the divergent synthetic backbone modification platform. The method already allows linear and parallel synthesis from commercially available nucleosides via standard phosphoramidite synthesis and avoids the purification of sensitive intermediates.

Efforts in this PoC will be focussed on diastereoselective oligonucleotide backbone modifications, the corresponding IP protection, licensing of the innovation as part of research collaborations with the pharmaceutical industry, and the creation of a spinout company.

Topics

Who is involved

OrganisationCityCountryRole
Universitat BaselBaselSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI